Core Viewpoint - The 10th China Pharmaceutical Innovation and Investment Conference highlighted the significant role of capital markets in supporting the globalization of Chinese innovative pharmaceutical companies, with Hong Kong Stock Exchange (HKEX) emerging as a leading platform for biotech financing in 2023 [1] Group 1: Market Performance - HKEX has positioned itself as a vital international financing platform for Chinese biotech companies, with the healthcare sector's IPO financing in Hong Kong ranking first globally this year [1] - As of now, Hong Kong has completed 12 biotech IPOs, raising a total of $1.3 billion, which is the highest globally [1] - The total amount raised through refinancing in the biotech sector has reached $4.1 billion this year, indicating a recovery in market confidence [1] Group 2: Regulatory Environment - The recent strong performance of Hong Kong's healthcare financing market is attributed to three interlinked factors: continuous optimization of regulatory systems, the listing of high-quality innovative companies, and active participation from investors [1] - The market is expected to see a significant rebound by 2025, reaffirming Hong Kong as the preferred listing destination for biotech companies [1]

张凌表示，欧洲已不再是Biotech等生物科技融资的热门区域，很多欧洲企业更倾向去美国融资，甚至 有不少大型药企如 阿斯利康等，考虑将上市地区，从伦敦转去美国。 不过他也提到一个值得关注的趋势，在过去一到两年，企业首选美国，目标进入美国资本市场，做 Crossover融资，甚至部分公司为了在美上市而转移注册地。 据瑞恩小编统计，今年(截至8月11日)香港新上市的55家中，14家来自医疗健康行业、占比25.5%。 来源：MoneyDJ 花旗集团投资银行医疗健康部亚太区主管 (Managing Director, Head of Asia Pacific Healthcare Investment Banking at Citigroup)张凌(Ling Zhang)周一(8月11日)在亚太生物科技投资论坛上表示，欧洲 生物科技融资热度下降，企业首选是去美国以及亚太市场，十二个月以前首选都是美国，但过去六个月 发生天翻地覆改变，出现东升西降趋势，不仅有中国资金的北水，国际资金也有积极参与。 但过去6个月出现东升西降趋势，香港资本市场突发猛进，美国生物科技资本市场反而相对安静。 他以指数举例，香港生物科技ETF今年 ...